pharmaphorum

MARCH 3, 2022

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. Cheaper options are meanwhile becoming available.

Biosimilars 52

Biosimilars Diabetes Mayo Clinic 52

PharmaShots

MARCH 29, 2023

Some companies accept the offered period and open doors to biological drugs or biosimilars. Indication: Type 2 Diabetes Mellitus Victoza is a non-insulin, anti-diabetic medicine used for the treatment of type 2 diabetes and to reduce the risk of cardiovascular events associated with the disease.

Biosimilars 49

Biosimilars Diabetes Chemotherapy Immunity 49

PharmaShots

APRIL 13, 2023

The company experienced significant challenges with patent expiration in 2018 Pfizer recorded substantial advancements in 2016 with the approval of five drugs and $52.8 as compared to 2018 Novartis recorded sales of $52B, Sandoz division contributed 19% of the group's total net sales. The consumer health business growth was 6.1%

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40

Quality Matters

APRIL 4, 2023

USP standards build trust in biologics and biosimilars The field of biologics is vast and growing, with tremendous potential to improve patients’ lives and public health. Shortening development timelines In 2018, it took approximately 18 months to bring a new mAb drug from discovery stage to the first human clinical trials.

Biosimilars 52

Biosimilars Vaccines Drug Development Diabetes 52

pharmaphorum

DECEMBER 2, 2020

Others rapidly followed, including Glucotrol, aimed at diabetics, and Procardia, an anti-hypertensive. In 2015 the company also paid $17 billion to acquire Hospira , a firm specialising in injectable drugs and biosimilars, at a time when copycat biologics were starting to make real waves in the market. billion.

Compounding 128

Compounding Vaccines Biosimilars Diabetes 128

PharmaShots

APRIL 3, 2023

multiple indications such as RA & Crohn's disease Hyrimoz was originally approved by the EC in 2018 with a concentration of 50mg/mL. multiple indications such as RA & Crohn's disease Hyrimoz was originally approved by the EC in 2018 with a concentration of 50mg/mL. events/100 patient-yrs.) The authorization incl.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

RX Note

FEBRUARY 23, 2023

. - Drug registration number Medicines (Advertisement & Sale) Act 1956 and Regulations - To learn prohibitions of medicine advertisement and Medicine Advertisement Board Registration of Pharmacists Act 1951 and Regulations - Pharmacy Board Malaysia and legislation aspects of provisional, full and temporary registration Code of Ethics for Pharmacists (..)

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58

Express Pharma

JANUARY 3, 2025

While India was able to leverage the 2008 patent cliff of small molecules, the same playbook will not work for biologics and biosimilars. Many biopharma companies in India have already leveraged the biosimilar patent cliff. Biocon became the first company from India to launch its biosimilar Hulio in the US in July 2023.

Biosimilars 105

Biosimilars Vaccines Diabetes 105